Enovis Corporation is set to announce its latest quarterly earnings on Wednesday, May 6th, with a consensus estimate of $0.82 earnings per share.
Enovis Corporation (ENOV) is currently priced at $23.46, experiencing a price drop of $1.08 (-4.4%) from the previous close. Trading volume stands at $145,658, representing a 14.51% deviation from the average.
In the most recent earnings report on Wednesday, February 25th, Enovis Corporation reported earnings per share of $0.95, surpassing the consensus estimate of $0.81.
Enovis Corporation's cash flow shows positive trends with operating cash flow at $88.54 million and a net change in cash of $2.77 million.
The company generated revenue of $575.76 million with a gross profit of $349.42 million. Enovis reported a net income of -$520.59 million, resulting in an earnings per share of -$9.17.
Key financial ratios for Enovis Corporation include a gross profit margin of 60.69%, return on equity of -34.95%, and a price-to-sales ratio of 2.63.
Enovis Corporation's balance sheet reflects total assets of $3.83 billion and total liabilities of $2.34 billion, with net debt amounting to $1.34 billion.
This comprehensive overview provides insight into Enovis Corporation's financial performance as investors await the upcoming earnings release.
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.